Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (7): 824-831.doi: 10.12092/j.issn.1009-2501.2023.07.014

Previous Articles     Next Articles

Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction

HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong   

  1. Hebei General Hospital, Shijiazhuang 050000, Hebei, China

  • Received:2022-11-15 Revised:2023-06-02 Online:2023-07-26 Published:2023-07-31

Abstract:

SGLT2 inhibitors currently have clear benefits in the treatment of heart failure whether combined with diabetes or not. Ventricular remodeling after myocardial infarction leads to the occurrence and development of heart failure, and eventually leads to death. There are relatively few studies on SGLT2 inhibitors in patients with myocardial infarction. The purpose of this article is to review the research progress of SGLT2 inhibitors application before and after myocardial infarction.

Key words: acute myocardial infarction, sodium-dependent glucose transporters 2 inhibitors, ventricular remodeling, heart failure

CLC Number: